Meet the Team
Experienced interdisciplinary team members including specialists in infectious diseases, molecular biologists, organic chemists, and industry executives
Executive Management
Advisor
Charlotte Dyring
Dr Dyring is an experienced project manager and HR manager with a solid understanding of the biotech industry. She is CEO of Marigold Innovation, and co-founder and former CEO of ExpreS²ion Biotechnologies, listed on Nasdaq First North Stockholm (EXPRS2). Furthermore, she played an essential role in establishing AdaptVac ApS, a Danish company with a COVID-19 vaccine in clinical phase 2 together with Bavarian Nordic.
CFO & Co-founder
Claus Hansen
Mr. Hansen is an experienced serial entrepreneur working with early-stage Life Science companies in various roles such as co-founder, certified and examined board member, and chief executive and strategic advisor. His preferred choice of companies and business cases are within the initial start-up phase and growth-and-business-development phase, including go-to-market strategy, commercialisation plans, and scaling, where he focuses on building value for shareholders.
CMO & Co-founder
Lars Jørgen Østergaard
Prof. Østergaard, MD, PhD is a Professor at AU in the Department of Clinical Medicine, and Chief Physician at the Department of Infectious Diseases at AU Hospital. His research includes virology and immunology and involves animal studies and clinical trials of new drugs and vaccines. He is also a co-founder and board member of the AU spin-off biotech company ISD Immunotech, which develops new anti-inflammatory strategies for treating severe immune-mediated diseases.
Key Academic Partners
Rikke Louise Meyer
Dr Meyer is an Associate Professor in Microbiology at AU and heads an interdisciplinary research group with postdocs and students in the fields of physics, nanoscience, chemistry, biology, and medicine. Her research focus is to: 1) understand how bacteria form antibiotic-tolerant biofilms, 2) develop technologies that prevent biofilm formation, and 3) develop new treatments that eradicate antibiotic-tolerant infections more effectively than current therapies.
Jes S. Lindholt
Prof. Jes Lindholt is a leading expert in aortic aneurism and vascular implants at Odense University Hospital. Prof. Lindholt has considerable experience working with the porcine model that Pincer will use in the development programme.
Carsten Behr Andersen
Dr Andersen is an expert in vascular ultrasound and an experienced open and endovascular surgeon in the Department of Heart, Lung and Vascular Surgery at Aarhus University Hospital. Dr Behr Andersen has experience performing open surgeries in several porcine and
ovine models and will provide valuable advice regarding the animal models that Pincer will use in the development programme.
Key Industrial Partners
Peter Horn Møller
Dr Møller has a scientific background with a master in biochemistry and organic chemistry and a PhD in medical sciences. More than 20 years of industrial experience, first as a patent attorney and later as corporate responsible for partnering, IP strategy and licensing, has given Peter a solid track record of turning state-of-the-art science into great, intellectually protected products.
Erik Vinther
Mr. Vinther has a commercial background with a master in business economics, marketing and consumer behavior. He holds 30 years commercial experience from pharma, ranging from operational sales and marketing to global marketing leadership as well as driving commercial strategy and launch planning for two major global launches to ensure complete alignment between the launch strategy and development programme.
Niels Skjærbæk
Niels Skjærbæk is PhD in Medicinal Chemistry and has more than 25 years of experience in drug discovery from both large pharma and biotech. He is currently partner at Marigold Innovation ApS
co-founder of Conrig Pharma ApS. Conrig has a small molecule in clinical development for treatment of chronic cough (PIIa/b). Conrig Pharma was acquired by Melius Pharma AB in 2021.
Niels has solid experience in business development activities and generel drug development activity prioritisations.